- Molecular formula: C27H35N6ABOUT8P
- CAS# 1809249-37-3
- Molecular mass: 602.576
- 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
- Synonym: GS-5734
- Brand name: Veklury
- GS-441524 prodrug
- Patent# US-2020276219-A1, CN-111093627-A, etc.
Owner: Gilead Sciences, Inc.
- ChemSrc, PubChem
Remdesivir, sold under the brand name Veklury is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. Remdesivir is a prodrug that is intended to allow intracellular delivery of GS-441524 monophosphate and subsequent biotransformation into GS-441524 triphosphate, a ribonucleotide analogue inhibitor of viral RNA polymerase.
Mechanism of action
Remdesivir specifically inhibits the activity of the viral RNA-dependent RNA-polymerase (RdRp), essential in viral replication [3-5]Upon entry into the cell, Remdesivir is rapidly metabolized into a nucleoside monophosphate (GS-441542 MP), which is then further processed into an active triphosphate form (GS-441524). GS-441524 is an adenosine triphosphate (ATP) analog and is thus, able to be used as a substrate by viral RdRp. GS-441524 outcompetes ATP for incorporation into the newly synthesized RNA strand, ultimately causing premature termination of the RNA product. However, unlike classic chain-terminators, the incorporation of GS-441524 causes delayed chain-termination downstream of this site [3, 4]. Importantly, it has been established that GS-441524 evades proofreading by the viral exoribonuclease (ExoN) .
Using Remdesivir for FIP treatment
The remdesivir company produces for legal veterinary use Bova at a concentration of 10mg/ml in 10ml vials.
For severe cases of FIP, intravenous administration is also possible at the beginning of treatment.
FIP treatment success rate is about 85-90%.
|Wet/Dry FIP||Ocular FIP||Neurological FIP|
|7-8 mg / kg||10 mg / kg||12-15 mg / kg|
- Warren, TK et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381–385.
- Gordon, CJ et al. 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem
- Gordon, CJ et al. 2020. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295, 6785–6797.
- Tchesnokov, EP et al. 2019. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses 11
- Agostini, ML et al. 2018. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio 9
- Remdesivir on Wiki
- Treatment of FIP in cats with Remdesivir